Welcome to UK420

Register now to gain access to all of our features. Once registered and logged in, you will be able to contribute to this site by submitting your own content or replying to existing content. You'll be able to customize your profile, receive reputation points as a reward for submitting content, while also communicating with other members via your own private inbox, plus much more!

This message will be removed once you have signed in.


2,111 topics in this forum

    • 365 replies
    • 187,636 views
    • 10 replies
    • 374 views
    • 3 replies
    • 85 views
    • 12 replies
    • 360 views
    • 4 replies
    • 107 views
    • 8 replies
    • 243 views
    • 1 reply
    • 141 views
    • 5 replies
    • 465 views
    • 42 replies
    • 2,536 views
    • 8 replies
    • 183 views
    • 0 replies
    • 141 views
    • 5 replies
    • 255 views
    • 8 replies
    • 309 views
    • 36 replies
    • 1,274 views
    • 1 reply
    • 219 views
    • 3 replies
    • 238 views
    • 5 replies
    • 270 views
    • 11 replies
    • 375 views
    • 4 replies
    • 237 views
    • 14 replies
    • 338 views
    • 2 replies
    • 262 views
    • 26 replies
    • 678 views
    • 1 reply
    • 209 views
    • 3 replies
    • 356 views
    • 2 replies
    • 337 views


  • Posts

    • The Padawan
      Hello buddy and welcome. Nice one on the first grow. Hard to beat smoking your own. Get a diary up for your next grow 
    • twoscoops
      Just sharing a few more Critical + 2.0 (sugar monster) :               Cheers scoops  .
    • bongme
      hi   GW Pharmaceuticals and the cannabis biotech firms   From Australia to the UK, companies are using compounds found in cannabis as ingredients in medicinal drugs.       Before the rise of the Canadian unicorns, a secret location in southeast England was said to be the largest legal cannabis growing site in the world. Founded by two British doctors, GW Pharmaceuticals [GWPH] has produced hundreds of tonnes of cannabis at its guarded site since launching in 1998.
       
      Despite the UK announcing plans only in July to allow doctors to prescribe a wide range of medicines made from cannabis, the government has already handed out swathes of licences for growing the drug. In 2010, almost a decade before the US, the British government was also one of the first to approve a medicine that contains marijuana: GW’s Sativex, a spray used to treat symptoms related to multiple sclerosis. GW made history again in 2018 when another drug it produces became the first to contain naturally derived cannabis to be approved by the FDA in the US.    An industry in development
      With a growing number of international licences and new drugs in the pipeline, many are extremely bullish on GW’s outlook. The company was up by 40% over the past year, and 1,500% since floating on the NASDAQ in 2013. Before GW, cannabis pharmaceuticals in the US had been dominated by companies that worked around prohibition by synthesising the effects of cannabis. Established companies with a range of medicines such as AbbVie [ABBV], Corbus Pharmaceuticals [CRBP], Cara Therapeutics [CARA], and Insys Therapeutics [INSY] have all developed drugs using an artificial cannabinoid that was first approved by the FDA in 1985. With these companies having a hold on a synthetic form that has already been produced, distributed and marketed, it’s perhaps not surprising that many are against legalising the natural stuff: Insys Therapeutics, which has lost 82% of its value since 2015, has spent $500,000 lobbying against the legalisation of cannabis in Arizona. Therapix Biosciences [TRPX] – a company set up to develop medicines from the synthetic THC form – has also suffered over the past year, losing nearly half of its value.    Diversifying the market
      Aside from GW, other companies concentrating on producing medicines from naturally occurring cannabinoids include Australia’s Medlab Clinical [MDC] and Zelda Therapeutics [ZLD]. The existing biotech companies operating in this space live in a very different world and offer a completely alternative proposition to the market than medical marijuana growers and distributors in the US or Canada. With regulatory approval, they function as any other pharmaceutical company, and are at far less risk from changes in laws.
       
      It might be one reason why Canada’s largest cannabis producer, Canopy Growth [CGC], is also now setting its sights on medicines. According to Bruce Linton, the company’s CEO, it plans to “completely disrupt the pharmaceuticals industry, from sleep to oncology”. Canopy Growth recently started clinical trials in Canada, where it is investigating how different combinations of molecules found in cannabis can be used to treat a variety of illnesses. It is also part of a “multi-million pounds” joint venture in the UK with Lady Amanda Feilding’s Beckley Foundation. If successful, Canopy Growth will become the first plant seller to properly cross over into the pharmaceutical industry.   https://www.cmcmarkets.com/en-gb/opto/gw-pharmaceuticals-and-the-cannabis-biotech-firms   Bongme     
    • HeavySmoker
      Damn they do look nice

      I will be looking to upgrade in a few months